rs11881222
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_172139.4(IFNL3):c.259-126T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.281 in 1,480,780 control chromosomes in the GnomAD database, including 59,929 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★).
Frequency
Consequence
NM_172139.4 intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IFNL3 | NM_172139.4 | c.259-126T>C | intron_variant | Intron 2 of 4 | ENST00000413851.3 | NP_742151.2 | ||
IFNL3 | NM_001346937.2 | c.271-126T>C | intron_variant | Intron 3 of 5 | NP_001333866.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IFNL3 | ENST00000413851.3 | c.259-126T>C | intron_variant | Intron 2 of 4 | 1 | NM_172139.4 | ENSP00000409000.2 | |||
IFNL3 | ENST00000613087.5 | c.271-126T>C | intron_variant | Intron 3 of 5 | 1 | ENSP00000481633.1 |
Frequencies
GnomAD3 genomes AF: 0.297 AC: 44904AN: 151146Hom.: 6925 Cov.: 29
GnomAD4 exome AF: 0.279 AC: 370626AN: 1329516Hom.: 52993 Cov.: 23 AF XY: 0.277 AC XY: 181980AN XY: 656916
GnomAD4 genome AF: 0.297 AC: 44959AN: 151264Hom.: 6936 Cov.: 29 AF XY: 0.291 AC XY: 21496AN XY: 73894
ClinVar
Submissions by phenotype
peginterferon alfa-2a response - Efficacy Other:1
PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy
ribavirin response - Efficacy Other:1
PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy
peginterferon alfa-2b response - Efficacy Other:1
PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at